Businessweek

Onyx Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 10:30 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Matthew K. Fust, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

Onyx Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total revenue of $145,492,000 against $72,031,000 a year ago. Loss from operations was $28,473,000 against $50,751,000 a year ago. Loss before provision for income taxes was $33,653,000 against $56,194,000 a year ago. Net loss was $33,671,000 against $56,212,000 a year ago. Net loss per diluted share was $0.47 against $0.88 a year ago. Non-GAAP net loss was $13,748,000 against $43,489,000 a year ago. Net loss per diluted share on non-GAAP basis was $0.19 against $0.68 a year ago.

Onyx Pharmaceuticals, Inc. announced that they will report Q1, 2013 results After-Market on May 07, 2013

Onyx Pharmaceuticals, Inc., Q1 2013 Earnings Call, May 07, 2013

Onyx Pharmaceuticals, Inc. announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Stivarga tablets for the treatment of patients with metastatic colorectal cancer (mCRC). In September 2012, Stivarga was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. It was approved by the U.S. FDA for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate in February 2013. The approval of Stivarga by the MHLW is based on data from the international multicenter pivotal Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial which evaluated regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with mCRC, whose disease has progressed after approved standard therapies. The CORRECT study included 20 sites in Japan. In the United States, Stivarga is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. It is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.